Adial Pharmaceuticals Stock Today
| ADIL Stock | USD 1.00 0.01 1.01% |
Performance1 of 100
| Odds Of DistressOver 81
|
Adial Pharmaceuticals is selling for 1.0 as of the 30th of November 2024. This is a 1.01 percent increase since the beginning of the trading day. The stock's lowest day price was 0.99. Adial Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Adial Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2018 | Category Healthcare | Classification Health Care |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. The company has 6.41 M outstanding shares of which 175 K shares are presently shorted by private and institutional investors with about 0.65 trading days to cover. More on Adial Pharmaceuticals
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Adial Stock Highlights
| President CEO | Cary MBA | |||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAdial Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adial Pharmaceuticals' financial leverage. It provides some insight into what part of Adial Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Adial Pharmaceuticals (ADIL) is traded on NASDAQ Exchange in USA. It is located in 4870 Sadler Road, Glen Allen, VA, United States, 23060 and employs 4 people. Adial Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.41 M. Adial Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 6.41 M outstanding shares of which 175 K shares are presently shorted by private and institutional investors with about 0.65 trading days to cover.
Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35.
Check Adial Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAlmost 95.18 percent of Adial Pharmaceuticals outstanding shares are held by general public with 1.79 (percent) owned by insiders and only 3.03 % by other corporate entities.
Check Adial Ownership Details
Adial Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Abound Wealth Management | 2024-09-30 | 27.0 | |
| Royal Bank Of Canada | 2024-06-30 | 19.0 | |
| Qube Research & Technologies | 2024-06-30 | 8.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Headlands Technologies Llc | 2024-06-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 0.0 | |
| Virtu Financial Llc | 2024-06-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 83.6 K | |
| Manchester Capital Management Llc | 2024-09-30 | 48.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 45.5 K |
Adial Pharmaceuticals Historical Income Statement
Adial Stock Against Markets
Adial Pharmaceuticals Corporate Management
| Alex Lugovoy | Chief Officer | Profile | |
| Andrew Taubman | Vice Development | Profile | |
| Catherine Fratila | Controller | Profile | |
| MBA MBA | Treasurer CFO | Profile | |
| Lawrence CPA | Controller | Profile | |
| John JD | General Counsel | Profile |
Already Invested in Adial Pharmaceuticals?
The danger of trading Adial Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adial Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adial Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adial Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.